Jasper Therapeutics shares rise 1.71% after-hours as biotech sector growth and innovation drive investor optimism.

Jasper Therapeutics, Inc. rose 1.71% in after-hours trading, aligning with the recent news that the biotechnology sector is entering a dynamic growth phase, fueled by advances in gene therapy, AI-assisted drug discovery, and personalized medicine. Global biotech revenue is projected to grow from $1.55 trillion in 2024 to over $4.6 trillion by 2034, reflecting a surge in both investment and innovation. Venture funding is rebounding strongly, with billions pouring into early-stage companies developing transformative therapies. This creates a unique opportunity for small-cap and emerging biotech firms, which are often operating under the radar, tackling complex medical challenges with innovative approaches.